Bullous pemphigoid (BP) is the most common autoimmune blistering disease of the skin with immune-mediated pathogenesis type 2. It mainly affects elderly patients with several concomitant diseases. Treatment is difficult in refractory cases or when standard immunosuppressants are limited due to toxicity or contraindications. In a series of five patients with confirmed BP at the University Hospital Schleswig-Holstein, Campus Kiel, off-label dupilumab was used. All five patients achieved sustained clinical improvement, including reduction in disease activity and pruritus. No serious adverse events were reported, with only one case of manageable conjunctivitis. Dupilumab was well tolerated and produced significant clinical benefit in all patients. These findings support the evidence for its safety and effectiveness, but further studies are needed to assess its long-term potential.